Winners of the Stop TB Partnership Award for Excellence in Reporting on Tuberculosis announced in Lille, France

26 October 2011 – Lille, France - The Stop TB Partnership today announced the winners of the Award for Excellence in Reporting on Tuberculosis 2010. The award, which is supported by the Lilly MDR-TB Partnership, recognizes outstanding reporting and commentary in print and on the web that materially increases the public's knowledge and understanding of tuberculosis (TB) and multidrug-resistant tuberculosis (MDR-TB), in countries affected by the disease. The Partnership confers first, second and third prizes in two categories: for journalists from low- and middle-income countries and those from high-income countries*.

Low- and middle-income country category

First prize (US$ 3000): Bharathi Ghanashyam of India. Her blog, "Children and TB – the diagnostic challenges" tells the moving stories of three children affected by TB while highlighting the challenge of diagnosing the disease in this age group in India, where the problem is rampant.


Third prize (US$ 1000): Evelyn Lirri of Uganda. "Tuberculosis is curable but is still a silent killer in Uganda", published in the Saturday Monitor, challenges her country to do more to tackle its TB and TB/HIV epidemics.

High-income country category

First prize (US$ 3000): Michael Specter of the United States. His feature in the New Yorker, "A Deadly Misdiagnosis", warns of the dangers of TB misdiagnosis in India, which has the highest rate of TB in the world and also points to recently developed molecular tests as offering hope.


Third prize (US$ 1000): Jason Overdorf of the United States. His article, "India: As the middle class rises, so does tuberculosis", published in the Global Post, overturns misconceptions that TB affects only the poor, but instead is striking a growing number of affluent people in India.

The Stop TB Partnership is leading the way to a world without tuberculosis (TB), a disease that is curable but still kills three people every minute. Founded in 2001, the Partnership’s mission is to serve every person who is vulnerable to TB and ensure that high-quality treatment is available to all who need it. Our role is to ensure a bold vision for addressing TB and to coordinate and catalyse global efforts towards elimination of the disease.

Together our nearly 1000 partners are a collective force that is transforming the fight against TB in more than 100 countries. They include the World Health Organization – which hosts the partnership secretariat and is the major partner – government programmes, technical partners, research and funding agencies, NGOs, civil society and community groups and private sector.

The Lilly MDR-TB Partnership is a public-private initiative that encompasses global health and relief organizations, academic institutions and private companies and is led by Eli Lilly and Company. Its mission is to address the expanding crisis of multi-drug resistant tuberculosis (MDR-TB). The partnership is pursuing a comprehensive strategy to fight MDR-TB through increasing drug supply at concessionary prices; research; providing training in prevention, treatment, and surveillance; promoting awareness and community support programs and sharing drug manufacturing technology with nations most at risk of MDR-TB.

*World Bank criteria: [World Bank Country Classification](http://data.worldbank.org/about/country-classifications)

For further information, please contact:
Judith Mandelbaum-Schmid, Team Leader for Communications, Stop TB Partnership
+41 22 791 29 67, mobile +41 79 254 6835, email: schmidj@who.int.

Karen Van der Westhuizen, Communications and Advocacy Manager, Lilly MDR-TB Partnership
+41 22 306 0322, mobile +41 79 599 8879   email: Van_der_Westhuizen_karen@lilly.com